← Back to guidelines
Cardiology14 papers

Prosthetic aortic valve stenosis

Last edited: 4/10/2026

Overview

Transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) are treatments for severe aortic stenosis, leading to the implantation of a prosthetic aortic valve 12. TAVR is the preferred treatment for high-risk patients with severe aortic stenosis 1.

Management

  • For patients undergoing TAVR, vascular closure device strategies are employed to manage large-bore femoral arterial access complications 1.
  • FemoSeal-ProGlide is associated with lower risks of major vascular complications and major bleeding events post-TAVR 1.
  • AngioSeal-ProGlide demonstrates the lowest device failure rate for vascular closure post-TAVR 1.
  • Prostar is associated with a higher risk of nonmajor vascular complications post-TAVR 1.
  • In women, TAVR and SAVR show no significant difference in the composite of all-cause mortality or disabling stroke at 5 years 2.
  • Special Populations

  • Women: Women with aortic stenosis exhibit distinct anatomic and physiologic features 2. While TAVR shows an advantage over SAVR at 1-year follow-up in women, no significant difference is observed in all-cause mortality or disabling stroke between TAVR and SAVR at 5 years 2.
  • Key Recommendations

  • For patients undergoing transcatheter aortic valve replacement (TAVR), FemoSeal-ProGlide is associated with lower risks of major vascular complications and major bleeding events 1. (Evidence: Strong)
  • AngioSeal-ProGlide demonstrates the lowest device failure rate for vascular closure post-TAVR 1. (Evidence: Strong)
  • In women with aortic stenosis, transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) show no significant difference in the composite of all-cause mortality or disabling stroke at 5 years 2. (Evidence: Strong)
  • References

    1 Deng Y, Feng Y, He S, Zhou W, Zhang J. Comparative Effectiveness of Vascular Closure Device Strategies in Transcatheter Aortic Valve Replacement: A Network Meta-Analysis. Annals of vascular surgery 2026. link 2 Wolf SEM, Kucera JA, Gregg AC, Di Franco A, Rahouma M, Redfors B et al.. Five-Year Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Women: A Systematic Review and Meta-Analysis. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 2025. link

    Original source

    1. [1]
    2. [2]
      Five-Year Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Women: A Systematic Review and Meta-Analysis.Wolf SEM, Kucera JA, Gregg AC, Di Franco A, Rahouma M, Redfors B et al. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2025)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG